Generic placeholder image

Current Pharmaceutical Design

Author(s): Yu-Qian Hu, Zhi-Xin Wang, Kun Xiang, Yi-Sheng He, Ya-Ting Feng, Zong-Wen Shuai* and Hai-Feng Pan*

DOI: 10.2174/1381612827666211111152319

DownloadDownload PDF Flyer Cite As
Elevated Circulating Thrombomodulin Levels in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Page: [306 - 312] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Objectives: Thrombomodulin (TM) is closely related to the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE). However, current evidence on circulating TM levels in SLE patients is contradictory. We conducted this meta-analysis to more accurately assess circulating TM levels in patients with SLE and lupus nephritis (LN) and to analyze related influencing factors.

Methods: Systematic search of relevant documents was conducted in PubMed, Embase, and The Cochrane Library databases (up to 28 February 2021). Studies on the comparison of circulating TM between SLE patients and controls were screened and evaluated for inclusion. Random-effects model analysis was applied to calculate the combined standardized mean difference (SMD) with a 95% confidence interval (CI). Heterogeneity was estimated by Q statistics and I2.

Results: A total of 353 articles were identified, 14 provided adequate information for this study finally. The results illustrated that SLE patients had higher TM levels than healthy controls (SMD=0.38, 95% CI: 0.02 to 0.74, p=0.04). Circulating TM levels were increased in patients with active SLE compared to inactive SLE patients (SMD=1.12, 95% CI: 0.03 to 2.20, p=0.04). In addition, circulating TM levels of SLE patients with LN were higher than those without LN (SMD=4.55, 95% CI: 1.97 to 7.12, p=0.001).

Conclusion: The circulating TM levels in SLE patients are enhanced. In addition, circulating TM levels may be practical in reflecting the disease activity and nephritis involvement of SLE patients.

Keywords: Systemic lupus erythematosus, lupus nephritis, disease activity, thrombomodulin, blood clotting, endothelial injury.

[1]
Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365(22): 2110-21.
[http://dx.doi.org/10.1056/NEJMra1100359] [PMID: 22129255]
[2]
Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39(1): 9-22.
[http://dx.doi.org/10.1002/art.1780390103] [PMID: 8546744]
[3]
Kuryliszyn-Moskal A, Ciolkiewicz M, Klimiuk PA, Sierakowski S. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. Scand J Rheumatol 2009; 38(1): 38-45.
[http://dx.doi.org/10.1080/03009740802366050] [PMID: 18991188]
[4]
Atehortúa L, Rojas M, Vásquez GM, Castaño D. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediators Inflamm 2017; 2017: 9680729.
[http://dx.doi.org/10.1155/2017/9680729] [PMID: 28546658]
[5]
Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial dysfunction in patients with rheumatoid arthritis: the role of hypertension. Curr Hypertens Rep 2020; 22(8): 56.
[http://dx.doi.org/10.1007/s11906-020-01064-y] [PMID: 32671677]
[6]
Shestakova MV, Jarek-Martynowa IR, Ivanishina NS, et al. Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2005; 68(Suppl. 1): S65-72.
[http://dx.doi.org/10.1016/j.diabres.2005.03.009] [PMID: 15955379]
[7]
Mok CC, Poon WL, Lai JP, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010; 39(1): 42-9.
[http://dx.doi.org/10.3109/03009740903046668] [PMID: 20132070]
[8]
Kluz J, Kopeć W, Jakobsche-Policht U, Adamiec R. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis. Int Angiol J Int Union Angiol 2009; 28(3): 192-201.
[9]
Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000; 119(1): 189-95.
[http://dx.doi.org/10.1046/j.1365-2249.2000.01107.x] [PMID: 10606982]
[10]
Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood 2018; 132(2): 148-58.
[http://dx.doi.org/10.1182/blood-2017-12-768994] [PMID: 29866818]
[11]
Watanabe-Kusunoki K, Nakazawa D, Ishizu A, Atsumi T. Thrombomodulin as a physiological modulator of intravascular injury. Front Immunol 2020; 11: 575890.
[http://dx.doi.org/10.3389/fimmu.2020.575890] [PMID: 33042158]
[12]
Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78(4): 2249-52.
[http://dx.doi.org/10.1073/pnas.78.4.2249] [PMID: 7017729]
[13]
Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42(1): 117-22.
[http://dx.doi.org/10.1093/rheumatology/keg045] [PMID: 12509624]
[14]
Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76(10): 2024-9.
[http://dx.doi.org/10.1182/blood.V76.10.2024.2024] [PMID: 2173634]
[15]
Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18(2): 383-8.
[PMID: 8864450]
[16]
Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008; 37(5): 352-9.
[http://dx.doi.org/10.1080/03009740802007514] [PMID: 18666029]
[17]
Lee WF, Wu CY, Yang HY, et al. Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous. Pediatr Rheumatol Online J 2019; 17(1): 69.
[http://dx.doi.org/10.1186/s12969-019-0369-7] [PMID: 31651352]
[18]
Yao GH, Liu ZH, Zhang X, et al. Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis. Lupus 2008; 17(8): 720-6.
[http://dx.doi.org/10.1177/0961203308089441] [PMID: 18625649]
[19]
Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol 2001; 28(3): 514-9.
[PMID: 11296951]
[20]
Horák P, Scudla V, Hermanovó Z, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001; 20(5): 337-44.
[http://dx.doi.org/10.1007/s100670170023] [PMID: 11642515]
[21]
Santos MJ, Carmona-Fernandes D, Canhão H, Canas da Silva J, Fonseca JE, Gil V. Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk. PLoS One 2012; 7(9): e44668.
[http://dx.doi.org/10.1371/journal.pone.0044668] [PMID: 22962622]
[22]
Yu KYC, Yung S, Chau MKM, et al. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. Rheumatology (Oxford) 2021; 60(2): 737-50.
[http://dx.doi.org/10.1093/rheumatology/keaa370] [PMID: 32793966]
[23]
Tanaka A, Ito T, Kibata K, et al. Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. Lupus 2019; 28(9): 1120-7.
[http://dx.doi.org/10.1177/0961203319862865] [PMID: 31299881]
[24]
Whitlock RP, Chan S, Devereaux PJ, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29(21): 2592-600.
[http://dx.doi.org/10.1093/eurheartj/ehn333] [PMID: 18664462]
[25]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta- analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[26]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[27]
Cicarini WB, Duarte RCF, Ferreira KS, et al. Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus. Lupus 2020; 29(2): 182-90.
[http://dx.doi.org/10.1177/0961203319899478]
[28]
Cieślik P, Hrycek A. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. Autoimmunity 2015; 48(4): 242-50.
[http://dx.doi.org/10.3109/08916934.2014.983264] [PMID: 25401491]
[29]
Frijns CJ, Derksen RH, De Groot PG, Algra A, Fijnheer R. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol 2001; 125(1): 149-54.
[http://dx.doi.org/10.1046/j.1365-2249.2001.01520.x] [PMID: 11472438]
[30]
de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 2009; 206(2): 546-50.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.03.018] [PMID: 19389674]
[31]
Constans J, Dupuy R, Blann AD, et al. Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 2003; 30(9): 1963-6.
[PMID: 12966599]
[32]
Koarada S, Tsuneyoshi N, Haruta Y, et al. Effect of disease activity and corticosteroids on serum levels of soluble endothelial cell protein C receptor in patients with systemic lupus erythematosus. Mod Rheumatol 2009; 19(2): 173-9.
[http://dx.doi.org/10.3109/s10165-008-0143-z] [PMID: 19067109]
[33]
Mancardi D, Arrigo E, Cozzi M, et al. Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players? Eur J Clin Invest 2021; 51(2): e13441.
[http://dx.doi.org/10.1111/eci.13441] [PMID: 33128260]
[34]
Ferreira KS, Cicarini WB, Alves LCV, et al. Clinica chimica acta. International journal of clinical chemistry. Elsevier 2019.
[35]
Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 2013; 304(12): H1585-97.
[http://dx.doi.org/10.1152/ajpheart.00096.2013] [PMID: 23604713]
[36]
Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101(2): 363-71.
[http://dx.doi.org/10.1083/jcb.101.2.363] [PMID: 2991298]
[37]
Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 2012; 19: 34.
[http://dx.doi.org/10.1186/1423-0127-19-34] [PMID: 22449172]
[38]
Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34(1): 107-25.
[http://dx.doi.org/10.1007/s00281-011-0282-8] [PMID: 21805323]
[39]
Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res 2016; 118(9): 1392-408.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.306853] [PMID: 27126649]
[40]
Morser J. Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets 2012; 13(3): 421-31.
[http://dx.doi.org/10.2174/138945012799424606] [PMID: 22206250]
[41]
Banfi G, Bertani T, Boeri V, et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1991; 18(2): 240-8.
[http://dx.doi.org/10.1016/S0272-6386(12)80885-7] [PMID: 1867181]
[42]
Tomura S, Deguchi F, Marumo F, Aoki N. Enhanced presence of thrombomodulin in the glomeruli of lupus glomerulonephritis. Clin Nephrol 1994; 41(4): 205-10.
[PMID: 8026112]
[43]
van Aanhold CCL, Dijkstra KL, Bos M, et al. Reduced glomerular endothelial thrombomodulin is associated with glomerular macrophage infiltration in diabetic nephropathy. Am J Pathol 2021; 191(5): 829-37.
[http://dx.doi.org/10.1016/j.ajpath.2021.02.002] [PMID: 33617784]
[44]
Batko K, Krzanowski M, Gajda M, et al. Proteoglycan/glycosaminoglycan and collagen content in the arterial wall of patients with end-stage renal disease: New indicators of vascular disease. Pol Arch Intern Med 2019; 129: 781-9.
[45]
Takeshita A, Yasuma T, Nishihama K, et al. Thrombomodulin ameliorates transforming growth factor-β1-mediated chronic kidney disease via the g-protein coupled receptor 15/akt signal pathway. Kidney Int 2020; 98(5): 1179-92.
[http://dx.doi.org/10.1016/j.kint.2020.05.041] [PMID: 33069430]